Diabetes Education News

Susan Weiner, MS, RDN, CDN, CDCES, FADCES, talks with Joshua J. Neumiller, PharmD, CDCES, FADCES, FASCP, about nuances of using SGLT2 inhibitors and GLP-1 receptor agonists in type 1 diabetes, and a therapy for delaying type 1 diabetes onset.

Presentations on the latest cardiometabolic research, panel discussions and updated practice recommendations are among this year’s highlights at the 21st World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease.

Most adults who are eligible for statin use to prevent CVD are not receiving them, according to a study published in Annals of Internal Medicine.

Higher BMI increased the risk for obesity-related cancer among a cohort of European adults, irrespective of cardiometabolic disease status, according to study results.

The new continuous glucose monitoring metric Glycemia Risk Index better assesses hypoglycemia risk than time in range, according to study data.

Five obesity advocacy organization have issued a joint statement asking the FDA to mandate that all drug approval trials include people with obesity.

Walking at a faster speed may decrease the risk for developing type 2 diabetes, though more studies are needed to confirm the association, according to findings from a systematic review and meta-analysis.

Pregnant women with type 2 diabetes who used continuous glucose monitoring only had improvements in CGM metrics if they used the device more than 50% of the time, according to data published in Diabetes Technology & Therapeutics.

Free weekly deliveries of fresh fruits and vegetables alongside nutritional counseling significantly reduced blood sugar among adults with type 2 diabetes, a speaker reported.

Statin therapy is a first-line recommendation for all adults with established atherosclerotic cardiovascular disease or at high atherosclerotic CVD risk, yet reports show many patients cannot — or will not — take statins as prescribed.